Lymphoma Clinical Trial
Official title:
Pilot Study Evaluating the Use of Proton Radiation for Treatment of Lymphoma Involving the Mediastinum
This research study is a Pilot Study. Pilot studies are conducted to see if it is practical
to do this type of research on a larger scale in the future. The pilot part of this study is
to assess the possibility of using proton radiation to treat lymphomas. Proton radiation is
used for many other types of malignancies, but its use for the treatment of lymphoma has been
limited. The treatment is still being studied as research doctors are trying to find out more
about its use in the treatment of different types of lymphoma. Proton beam radiation therapy
is an FDA approved radiation delivery system.
Patients are being asked to participate in this research study if they have lymphoma in the
center of their chest, near their heart. Conventional radiation therapy with photons is used
as standard treatment for many patients with lymphoma. In this research study investigators
are looking at another type of radiation called proton radiation, which is known to spare
surrounding tissue and organs from radiation. Proton radiation delivers radiation to the area
requiring radiation but delivers no dose beyond the region requiring treatment. This may
reduce side effects that patients would normally experience with conventional radiation
therapy or other means of delivering proton radiation therapy.
In this research study, investigators are evaluating the effectiveness of using proton
radiation delivered to reduce side effects associated with radiation treatment.
If a person agrees to participate in this research study, they will be asked to undergo some
screening tests or procedures to confirm eligibility. Many of these tests and procedures are
likely to be part of regular cancer care and may be done even if it turns out that a patient
does not take part in the research study. If a patient has had some of these tests or
procedures recently, they may or may not have to be repeated. These tests and procedures
include: a medical history, performance status, physical examination, assessment of tumor,
echocardiogram, electrocardiogram, pulmonary (lung) function tests and blood tests. If these
tests show that a patient is eligible to participate in the research study, they will begin
the study treatment. If a patient does not meet the eligibility criteria, they will not be
able to participate in the research study.
Proton radiation will be delivered daily for 2 to 5 weeks, depending on the dose prescribed
by your physician. Treatment is delivered (Monday-Friday) for 5 days (no weekends or
holidays). Each treatment will require that you lie on a table for 30 to 45 minutes.
Participants will receive radiation therapy as an outpatient at Massachusetts General
Hospital. During radiation therapy, they will have the following weekly assessments and
procedures: physical exam, assess for any side effects, blood tests for cardiac markers.
Study participants will be asked to return for a follow up visit 6-12 weeks after their last
dose of radiation therapy. During this visit the following tests and procedures will be done:
PET/CT scan, physical exam, assess for side effects and blood tests for cardiac markers.
Participants will also be asked to return for a follow-up visit at 6 months, 12 months and
annually for five years post radiation. Keeping in touch with study participants and checking
on their condition helps investigators look at the long-term effects of the research study.
At these visits, the following tests and procedures will be done: physical exam, assess for
any side effects, ECG, ECHO, pulmonary tests, PET/CT scan, routine blood tests and blood
tests for cardiac markers (at 6 months and 1 years only).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
| Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
| Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
| Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
| Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
| Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
| Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
| Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
| Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
| Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
| Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
| Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |